Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA

GlobeNewswire April 4, 2018

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire March 30, 2018

Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference

GlobeNewswire March 28, 2018

FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne

PR Newswire December 20, 2017

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2017

Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018

GlobeNewswire November 8, 2017

Paratek Pharmaceuticals Inc to Host Earnings Call

Accesswire November 8, 2017

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2017

Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017

GlobeNewswire October 24, 2017

Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria

GlobeNewswire October 6, 2017

Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions

GlobeNewswire October 6, 2017

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2017

Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017

GlobeNewswire September 25, 2017

Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections

GlobeNewswire September 21, 2017

Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017

GlobeNewswire September 19, 2017

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 1, 2017

Daily Technical Summary Reports on Biotech Stocks -- Paratek Pharma, Pulmatrix, Verastem, and Biostage

PR Newswire August 24, 2017

Mid-Afternoon Market Update: Crude Oil Up Over 1%; Express Shares Rise After Strong Q2 Results

Benzinga.com  August 23, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  August 23, 2017

Mid-Morning Market Update: Markets Open Lower; Lowe's Earnings Miss Expectations

Benzinga.com  August 23, 2017